News >

Niraparib Active in Heavily Pretreated Ovarian Cancer, Regardless of BRCA Status

Jason M. Broderick @jasoncology
Published: Tuesday, Apr 24, 2018

Mary Lynne Hedley

Mary Lynne Hedley, PhD
Niraparib (Zejula) met the primary endpoint of overall response as a fourth-line or later treatment in patients with ovarian cancer, regardless of BRCA status, according to top-line results from the QUADRA study announced by TESARO, the manufacturer of the PARP inhibitor. 

In the phase II open-label, single-arm study, niraparib induced an overall response rate (ORR) of 29% and a duration of response (DOR) of 9.2 months among homologous recombination deficiency (HRD)–positive, PARP inhibitor–naive, platinum-sensitive patients receiving treatment in the fourth- or fifth-line setting (n = 45).

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ASCO Direct™ Highlights – 2019 Official Annual Meeting ReviewAug 30, 20201.5
Community Practice Connections™: Advances in Ovarian Cancer: Evolving Applications for PARP Inhibitors, Immunotherapy & Beyond!Aug 30, 20201.5
Publication Bottom Border
Border Publication